BACKGROUND AND PURPOSE: Patients in poor clinical condition (Hunt and Hess grade 4
or 5) after subarachnoid hemorrhage (SAH) have historically fared poorly and many often …

Background and Purpose— The optimal approach for acute ischemic stroke patients who do
not respond to intravenous recombinant tissue plasminogen activator (IV rt-PA) is uncertain. …

Background and Purpose— Studies have established a relation between recanalization and
improved clinical outcome in acute ischemic stroke patients; however, intra-arterial clot size …

Thrombolysis remains a mainstay in the treatment of ischemic stroke. While not usually
considered in the spectrum of clot lysis, experimental data show that inhibition of the platelet …

Background: Proven options to treat ischemic stroke patients ineligible for IV t-PA are limited.
Our focus is on treatments to spare the penumbral microcirculation. Evidence indicates that …

4098 Background: After Sorafenib failure,there is no effective systemic therapy for advanced
HCC. Preclinical data show upregulated mTOR signaling in HCC. We tested the IV mTOR …

… -100 Regular Pork Insulin following a negative intradermal skin test to l/1,000 U of the same
… 75 U without urticaria. The patient was discharged on day 13 taking 60 U of Single Peak U-…

… at an approximate rate of 0.1 U aliquots diluted in 1 mL normal saline for 1–2 minutes.
Urokinase and rtPA were injected in the same manner at a rate of 50,000–200,000 U and 1–4 mg …

BACKGROUND AND PURPOSE: Patients in poor clinical condition (Hunt and Hess grade 4
or 5) after subarachnoid hemorrhage (SAH) have historically fared poorly and many often …